Sugi Predict

Sugi Predict / Compounds / SCHEMBL184552

SCHEMBL184552

SCHEMBL184552

COC(=O)c1ccc(CBr)c(OC)c1

nearest known ligand 0.57

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ MAPT P10636 7/20 0.57
▸ KMT2A Q03164 5/20 0.51
▸ MEN1 O00255 4/20 0.48
▸ CA1 P00915 2/20 0.47
▸ CA2 P00918 2/20 0.47
▸ CA12 O43570 1/20 0.47
▸ CA7 P43166 1/20 0.47
▸ XDH P47989 1/20 0.47
▸ CA9 Q16790 1/20 0.47
▸ CA14 Q9ULX7 1/20 0.47
▸ HIF1A Q16665 1/20 0.47
▸ TSHR P16473 2/20 0.46
▸ HSD17B2 P37059 1/20 0.46
▸ MGLL Q99685 1/20 0.46
▸ SMN1; SMN2 Q16637 3/20 0.46
▸ KDM4E B2RXH2 3/20 0.46
▸ ALDH1A1 P00352 2/20 0.46
▸ NPC1 O15118 2/20 0.46
▸ RAB9A P51151 2/20 0.46
▸ PKM P14618 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL11059045 0.88 HIF1A (0.47) MAPTKMT2AMEN1CA1CA2
SCHEMBL5832949 0.87 MAPT (0.54) MAPTKMT2AMEN1CA1CA2
SCHEMBL854310 0.87 MAPT (0.57) MAPTKMT2AMEN1CA1CA2
SCHEMBL30036339 0.87 MAPT (0.57) MAPTKMT2AMEN1CA1CA2
SCHEMBL8429886 0.86 MAPT (0.60) MAPTKMT2AMEN1CA1CA2
SCHEMBL5161173 0.86 HSD17B2 (0.66) MAPTKMT2AMEN1CA1CA2
SCHEMBL1017686 0.86 RAB9A (0.52) MAPTKMT2AMEN1CA1CA2
SCHEMBL2827834 0.86 ALDH1A1 (0.47) MAPTKMT2AMEN1CA1CA2
SCHEMBL2252810 0.85 MAPT (0.58) MAPTKMT2AMEN1CA1CA2
SCHEMBL2784039 0.85 CA12 (0.62) CA1CA2CA12CA7CA9

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 784 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-108084077-A A kind of synthetic method of zafirlukast intermediate 江汉大学 2018-05-29 — — CN claimed
US-20090149662-A1 PROCESSES FOR PREPARING ZAFIRLUKAST DR. REDDY'S LABORATORIES LIMITED (IN) 2009-06-11 — — US claimed
JP-6279404-A — — None — — JP disclosed
US-12534465-B2 5H-pyrrolo[3,2-d]pyrimidine-2,4-diamino compounds and antibody conjugates thereof SUTRO BIOPHARMA, INC. (US) 2026-01-27 — — US disclosed
EP-4680226-A2 ACYLSULFONAMIDE KAT6A INHIBITORS Olema Pharmaceuticals, Inc. (US) 2026-01-21 — — EP disclosed
US-20260015327-A1 ACYLSULFONAMIDE KAT6A INHIBITORS OLEMA PHARMACEUTICALS INC (US) 2026-01-15 — — US disclosed
US-20250312471-A1 ANTIBODY-DRUG COMPLEX CONTAINING TOLL-LIKE RECEPTOR 7/8 DUAL AGONIST COMPOUND ASTELLAS PHARMA INC. (JP) 2025-10-09 — — US disclosed
WO-2025201504-A1 KAT6 INHIBITORS BEIGENE (SUZHOU) CO., LTD. (CN) 2025-10-02 — — WO disclosed
US-20250304535-A1 KAT6 Inhibitors BEIGENE SWITZERLAND GMBH (CH) 2025-10-02 — — US disclosed
US-12428379-B2 Acylsulfonamide KAT6A inhibitors OLEMA PHARMACEUTICALS, INC. (US) 2025-09-30 — — US disclosed
US-20250296935-A1 Diamine Derivatives as Inhibitors of Leukotriene A4 Hydrolase CELLTAXIS LLC (US) 2025-09-25 — — US disclosed
EP-0242167-A2 Heterocyclic carboxamides ICI AMERICAS INC. (US) 1987-10-21 — — EP disclosed
EP-0227241-A2 Medicinal indole and indazole keto sulphone derivatives ZENECA INC. (US) 1987-07-01 — — EP disclosed
EP-0220066-A2 Carboxamide derivatives ICI AMERICAS INC. (US) 1987-04-29 — — EP disclosed
US-4654371-A ANTI-OBESITY, HYPOGLYCEMIA AGENTS BEECHAM GROUP P.L.C. (GB) 1987-03-31 — — US disclosed
EP-0199543-A2 Heterocyclic amide derivatives ICI AMERICAS INC. (US) 1986-10-29 — — EP disclosed
EP-0179619-A1 Heterocyclic amides ICI AMERICAS INC. (US) 1986-04-30 — — EP disclosed
US-4478849-A HYPERGLYCEMIC AGENTS BEECHAM GROUP LIMITED (GB) 1984-10-23 — — US disclosed
EP-0006735-B1 SECONDARY AMINES, THEIR PREPARATION, PHARMACEUTICAL COMPOSITIONS CONTAINING THEM AND THEIR USE BEECHAM GROUP PLC (GB) 1983-06-15 — — EP disclosed
EP-0006735-A1 Secondary amines, their preparation, pharmaceutical compositions containing them and their use BEECHAM GROUP PLC (GB) 1980-01-09 — — EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250312471-A1 ANTIBODY-DRUG COMPLEX CONTAINING TOLL-LIKE RECEPTOR 7/8 DUAL AGONIST COMPOUND TLR7, TLR1, TLR2 MAPT 3605/4885KMT2A 933/4885MEN1 2992/4885
US-20250304535-A1 KAT6 Inhibitors KAT6A, KAT6B, KAT2A MAPT 171/4885KMT2A 68/4885MEN1 3836/4885
US-12428379-B2 Acylsulfonamide KAT6A inhibitors KAT6A, KAT2A, KAT6B MAPT 2500/4885KMT2A 67/4885MEN1 4459/4885
US-20090149662-A1 PROCESSES FOR PREPARING ZAFIRLUKAST SI, FIP1L1, KHK MAPT 2286/4885KMT2A 4303/4885MEN1 2811/4885
US-20250296935-A1 Diamine Derivatives as Inhibitors of Leukotriene A4 Hydrolase LTA4H, LTB4R, LTC4S MAPT 4254/4885KMT2A 2617/4885MEN1 4161/4885
US-20260015327-A1 ACYLSULFONAMIDE KAT6A INHIBITORS KAT6A, KAT2A, KAT6B MAPT 3581/4885KMT2A 104/4885MEN1 4732/4885
US-12534465-B2 5H-pyrrolo[3,2-d]pyrimidine-2,4-diamino compounds and antibody conjugates thereof CD22, FCGR3B, FCGR2A MAPT 3561/4885KMT2A 1775/4885MEN1 3895/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.